FGF-18 alleviates memory impairments and neuropathological changes in a rat model of Alzheimer's disease

IF 2.5 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Neuropeptides Pub Date : 2023-10-01 DOI:10.1016/j.npep.2023.102367

Arzuhan Cetindag Ciltas , Sebahattin Karabulut , Bilal Sahin , Ahmet Kemal Filiz , Fatih Yulak , Mustafa Ozkaraca , Ozhan Karatas , Ali Cetin

{"title":"FGF-18 alleviates memory impairments and neuropathological changes in a rat model of Alzheimer's disease","authors":"Arzuhan Cetindag Ciltas , Sebahattin Karabulut , Bilal Sahin , Ahmet Kemal Filiz , Fatih Yulak , Mustafa Ozkaraca , Ozhan Karatas , Ali Cetin","doi":"10.1016/j.npep.2023.102367","DOIUrl":null,"url":null,"abstract":"<div>Alzheimer's disease (AD) is a multifactorial pathology marked by amyloid beta (Aβ) accumulation, tau hyperphosphorylation, and progressive cognitive decline. Previous studies show that fibroblast growth factor 18 (FGF18) exerts a neuroprotective effect in experimental models of neurodegeneration; however, how it affects AD pathology remains unknown. This study aimed to ascertain the impact of FGF18 on the behavioral and neuropathological changes in the rat model of sporadic AD induced by intracerebroventricular (ICV) injection of streptozotocin (STZ). The rats were treated with FGF18 (0.94 and 1.88 pmol, ICV) on the 15th day after STZ injection. Their cognitive function was assessed in the Morris water maze and passive avoidance tests for 5 days from the 16th to the 21st days. Aβ levels and histological signs of neurotoxicity were detected using the enzyme-linked immunosorbent assay (ELISA) assay and histopathological analysis of the brain, respectively. FGF18 mildly ameliorated the STZ-induced cognitive impairment; the Aβ accumulation was reduced; and the neuronal damage including pyknosis and apoptosis was alleviated in the rat brain. This study highlights the promising therapeutic potential for FGF18 in managing AD.</div>","PeriodicalId":19254,"journal":{"name":"Neuropeptides","volume":"101 ","pages":"Article 102367"},"PeriodicalIF":2.5000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropeptides","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0143417923000483","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer's disease (AD) is a multifactorial pathology marked by amyloid beta (Aβ) accumulation, tau hyperphosphorylation, and progressive cognitive decline. Previous studies show that fibroblast growth factor 18 (FGF18) exerts a neuroprotective effect in experimental models of neurodegeneration; however, how it affects AD pathology remains unknown. This study aimed to ascertain the impact of FGF18 on the behavioral and neuropathological changes in the rat model of sporadic AD induced by intracerebroventricular (ICV) injection of streptozotocin (STZ). The rats were treated with FGF18 (0.94 and 1.88 pmol, ICV) on the 15th day after STZ injection. Their cognitive function was assessed in the Morris water maze and passive avoidance tests for 5 days from the 16th to the 21st days. Aβ levels and histological signs of neurotoxicity were detected using the enzyme-linked immunosorbent assay (ELISA) assay and histopathological analysis of the brain, respectively. FGF18 mildly ameliorated the STZ-induced cognitive impairment; the Aβ accumulation was reduced; and the neuronal damage including pyknosis and apoptosis was alleviated in the rat brain. This study highlights the promising therapeutic potential for FGF18 in managing AD.

查看原文本刊更多论文

FGF-18减轻阿尔茨海默病大鼠模型的记忆障碍和神经病理改变

阿尔茨海默病（AD）是一种多因素病理学，其特征是淀粉样蛋白β（aβ）积累、tau过度磷酸化和进行性认知能力下降。先前的研究表明，成纤维细胞生长因子18（FGF18）在神经退行性变的实验模型中发挥神经保护作用；然而，它如何影响AD病理学仍然未知。本研究旨在确定FGF18对侧脑室内注射链脲佐菌素（STZ）诱导的散发性AD大鼠模型的行为和神经病理学变化的影响。在STZ注射后的第15天用FGF18（0.94和1.88pmol，ICV）处理大鼠。从第16天到第21天，在Morris水迷宫和被动回避测试中对他们的认知功能进行了为期5天的评估。分别使用酶联免疫吸附试验（ELISA）和脑组织病理学分析检测Aβ水平和神经毒性的组织学体征。FGF18轻度改善STZ诱导的认知障碍；Aβ积累减少；大鼠脑内包括固缩和细胞凋亡在内的神经元损伤减轻。这项研究强调了FGF18在治疗AD方面有前景的治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropeptides 医学-内分泌学与代谢

CiteScore

5.40

自引率

6.90%

发文量

审稿时长

>12 weeks

期刊介绍： The aim of Neuropeptides is the rapid publication of original research and review articles, dealing with the structure, distribution, actions and functions of peptides in the central and peripheral nervous systems. The explosion of research activity in this field has led to the identification of numerous naturally occurring endogenous peptides which act as neurotransmitters, neuromodulators, or trophic factors, to mediate nervous system functions. Increasing numbers of non-peptide ligands of neuropeptide receptors have been developed, which act as agonists or antagonists in peptidergic systems. The journal provides a unique opportunity of integrating the many disciplines involved in all neuropeptide research. The journal publishes articles on all aspects of the neuropeptide field, with particular emphasis on gene regulation of peptide expression, peptide receptor subtypes, transgenic and knockout mice with mutations in genes for neuropeptides and peptide receptors, neuroanatomy, physiology, behaviour, neurotrophic factors, preclinical drug evaluation, clinical studies, and clinical trials.